Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 16/20 | 0.75 |
| ▸ | TP53 | P04637 | 11/20 | 0.75 |
| ▸ | THRB | P10828 | 2/20 | 0.75 |
| ▸ | LMNA | P02545 | 4/20 | 0.72 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3321679 | 0.92 | MAPT (0.78) | MAPTTP53THRBLMNACA1 | |
| SCHEMBL3324225 | 0.86 | MAPT (0.79) | MAPTTP53THRBLMNA | |
| SCHEMBL3321687 | 0.83 | MAPT (0.81) | MAPTTP53THRBLMNA | |
| SCHEMBL3324668 | 0.82 | MAPT (0.70) | MAPTTP53THRBLMNAHPGD | |
| SCHEMBL3324330 | 0.79 | MAPT (0.78) | MAPTTP53THRBLMNACA1 | |
| SCHEMBL3325888 | 0.79 | MAPT (0.73) | MAPTTP53THRBLMNA | |
| SCHEMBL3323549 | 0.78 | MAPT (0.75) | MAPTTP53THRBLMNA | |
| SCHEMBL3322966 | 0.78 | MAPT (0.72) | MAPTTP53THRBLMNA | |
| SCHEMBL17425859 | 0.76 | MAPT (0.80) | MAPTTP53THRBLMNA | |
| SCHEMBL12076726 | 0.76 | MAPT (0.55) | MAPTTP53THRBLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139472-B1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2016-01-13 | — | — | EP | claimed |
| US-8288432-B2 | Tetrahydroindole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2012-10-16 | — | — | US | claimed |
| US-20100120749-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-05-13 | — | — | US | claimed |
| EP-2139472-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-01-06 | — | — | EP | claimed |
| EP-2000176-A1 | Tetrahydroindole derivatives as NADPH Oxidase inhibitors | GenKyo Tex (CH) | 2008-12-10 | — | — | EP | claimed |
| WO-2008116926-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2008-10-02 | — | — | WO | claimed |
| EP-2139472-B1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2016-01-13 | — | — | EP | disclosed |
| EP-2139472-B1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-8288432-B2 | Tetrahydroindole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2012-10-16 | — | — | US | disclosed |
| US-8288432-B2 | Tetrahydroindole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2012-10-16 | — | — | US | disclosed |
| US-8288432-B2 | Tetrahydroindole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20100120749-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-05-13 | — | — | US | disclosed |
| US-20100120749-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-05-13 | — | — | US | disclosed |
| US-20100120749-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-05-13 | — | — | US | disclosed |
| EP-2139472-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-01-06 | — | — | EP | disclosed |
| EP-2000176-A1 | Tetrahydroindole derivatives as NADPH Oxidase inhibitors | GenKyo Tex (CH) | 2008-12-10 | — | — | EP | disclosed |
| EP-2000176-A1 | Tetrahydroindole derivatives as NADPH Oxidase inhibitors | GenKyo Tex (CH) | 2008-12-10 | — | — | EP | disclosed |
| WO-2008116926-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116926-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120749-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | CYBB, NQO1, NOX4 | MAPT 1042/4885TP53 4124/4885THRB 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.